Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors - Concepedia

Concepedia

Publication | Open Access

Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors

DOI Full Paper Access

102

Citations

18

References

2013

Year

Suzanne George, Yang Feng, Judith Manola, Marisa R. Nucci, James E. Butrynski, Jeffrey A. Morgan, Nikhil H. Ramaiya, Richard Quek, Richard T. Penson, Andrew J. Wagner,

Abstract

Letrozole met protocol-defined criteria as an agent with activity in patients with advanced ULMS. Patients with the longest progression-free survival rate were those whose tumors strongly and diffusely expressed ER and PR.

References

	Year	Citations

Page 1